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Laminopathies are a clinically heterogeneous group of disorders caused by mutations in
LMNA. The main proteins encoded by LMNA are Lamin A and C, which together with
Lamin B1 and B2, form the nuclear lamina: a mesh-like structure located underneath the
inner nuclear membrane. Laminopathies show striking tissue specificity, with subtypes
affecting striated muscle, peripheral nerve, and adipose tissue, while others cause
multisystem disease with accelerated aging. Although several pathogenic mechanisms
have been proposed, the exact pathophysiology of laminopathies remains unclear,
compounded by the rarity of these disorders and lack of easily accessible cell types to
study. To overcome this limitation, we used induced pluripotent stem cells (iPSCs) from
patients with skeletal muscle laminopathies such as LMNA-related congenital muscular
dystrophy and limb-girdle muscular dystrophy 1B, to model disease phenotypes in vitro.
iPSCs can be derived from readily accessible cell types, have unlimited proliferation
potential and can be differentiated into cell types that would otherwise be difficult
and invasive to obtain. iPSC lines from three skeletal muscle laminopathy patients
were differentiated into inducible myogenic cells and myotubes. Disease-associated
phenotypes were observed in these cells, including abnormal nuclear shape and
mislocalization of nuclear lamina proteins. Nuclear abnormalities were less pronounced
in monolayer cultures of terminally differentiated skeletal myotubes than in proliferating
myogenic cells. Notably, skeletal myogenic differentiation of LMNA-mutant iPSCs in
artificial muscle constructs improved detection of myonuclear abnormalities compared
to conventional monolayer cultures across multiple pathogenic genotypes, providing
a high-fidelity modeling platform for skeletal muscle laminopathies. Our results lay the
foundation for future iPSC-based therapy development and screening platforms for
skeletal muscle laminopathies.
Keywords: lamin A/C, LMNA, skeletal muscle, laminopathies, muscular dystrophy, iPSCs, disease modeling, 3D
modeling
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INTRODUCTION
The LMNA gene encodes two major protein isoforms: Lamin A
and C; these nuclear intermediate filament proteins are expressed
in most somatic cells, but absent from undifferentiated cells
such as embryonic, germ and pluripotent cells (Dechat et al.,
2010a; Worman, 2012). At the nuclear periphery, Lamin A/C,
together with Lamin B1 and B2, forms the nuclear lamina, a
protein meshwork that underlies the nuclear membrane. The
nuclear lamina provides structural support to the nucleus, and
participates in mechanotransduction, heterochromatin tethering
and regulation of transcription (Azibani et al., 2014; Gruenbaum
and Foisner, 2015). Lamin A/C is also present in the nucleoplasm,
where it is thought to be involved in regulation of cell
proliferation, differentiation, chromatin organization and DNA
replication (Dechat et al., 2010b).
Mutations in LMNA cause at least 16 rare disorders,
collectively known as laminopathies (Scharner et al., 2010;
Worman, 2012). Laminopathies demonstrate tissue-specific
phenotypes and can be grouped into those affecting striated
cardiac and/or skeletal muscle (the most common group),
peripheral nerve or adipose tissue, and those causingmultisystem
disease with accelerated aging. Striated muscle laminopathies
are usually caused by missense mutations, typically having
a dominant inheritance and include dilated cardiomyopathy
(DCM), Emery-Dreifuss muscular dystrophy (EDMD), limb-
girdle muscular dystrophy type 1B (LGMD1B) and LMNA-
related congenital muscular dystrophy (L-CMD). While all
four have cardiac involvement, EDMD, LGMD1B and L-
CMD also affect skeletal muscle (Worman, 2012; Bonne and
Quijano-Roy, 2013; Azibani et al., 2014). However, genotype-
phenotype correlations are not always clear, with instances of
the same LMNA mutation causing different disorders (Scharner
et al., 2010, 2014; Bertrand et al., 2011). Two non-mutually
exclusive theories have been proposed to explain the pathological
causes of striated muscle laminopathies. In the mechanical
stress hypothesis, mutations in Lamin A/C lead to a nucleus
that is more vulnerable to damage from mechanical force
during muscle contraction. The gene expression and stem cell
differentiation hypothesis suggests that mutant Lamin A/C
deregulates expression of certain genes, which causes defective
cell differentiation and function (Azibani et al., 2014; Gruenbaum
and Foisner, 2015).
A typical cellular hallmark of LMNA mutations is abnormal
nuclear morphology, as observed in muscle biopsies of EDMD
patients (Park et al., 2009). Such nuclear abnormalities have
been modeled in vitro in primary fibroblasts and C2C12
myoblasts ectopically expressing pathogenic LMNA mutations.
Fibroblasts from patients with LGMD1B (Muchir et al., 2003),
autosomal dominant EDMD (Muchir et al., 2004), L-CMD
(Tan et al., 2015), DCM (Muchir et al., 2004), familial partial
lipodystrophy (FPLD) (Vigouroux et al., 2001; Verstraeten et al.,
2009), Mandibuloacral dysplasia (MAD) (Novelli et al., 2002),
Hutchinson-Gilford progeria syndrome (HGPS) (Eriksson et al.,
2003), and Werner syndrome 2 (WRN2) (Chen et al., 2003) all
have nuclear abnormalities, such as abnormal nuclear shape and
mislocalization of lamina proteins. These can be characterized by:
(1) mislocalization of Lamin A/C protein (e.g., into structures
with a honeycomb-like appearance), (2) nucleoplasmic foci
and/or increased nucleoplasmic/lamina ratios, (3) areas with
no lamin B1 (capping), and (4) Emerin mislocalization. C2C12
mouse myoblasts expressing EDMD/L-CMD-causing LMNA
mutations exhibit similar defects (Ostlund et al., 2001; Favreau
et al., 2003; Markiewicz et al., 2005; Scharner et al., 2011;
Barateau et al., 2017). However, not all LMNA-mutations produce
a morphological defect or have Lamin A/C mislocalization
(Ostlund et al., 2001; Muchir et al., 2004), which can depend on
the cell type assessed (e.g., patient fibroblasts vs. over-expression
in C2C12 myoblasts) (Barateau et al., 2017). Furthermore,
correlations between a particular laminopathy and the type
of nuclear shape and/or mislocalization defects have remained
elusive, with examples of different tissue specific disorders
causing the same type of mislocalizations and shape defects
(Vigouroux et al., 2001; Novelli et al., 2002; Muchir et al., 2004).
Understanding pathological events underlying laminopathies
andmaking genotype-phenotype correlations has been limited by
the rarity of these disorders, invasiveness of sampling and limited
proliferation/differentiation capacity of primary patient cells.
This has led to fibroblasts typically being studied as a primary cell
source, despite not being the disease-causing/-affected cell type
in most laminopathies. Induced pluripotent stem cells (iPSCs)
(Takahashi et al., 2007) offer a new approach to disease modeling
and drug screening (Ebert et al., 2012; Brandão et al., 2017).
IPSCs can be made from patient primary cells obtained from
minimally invasive sources, such as skin fibroblasts, blood or
urine cells, which can then be reprogrammed to pluripotency
and directed to differentiate into any cell type, enabling the study
of disease-/patient-specific cells that would otherwise be difficult
to obtain. iPSCs also possess a virtually unlimited expansion
potential, circumventing problems of cellular senescence of
primary cells. This is particularly important for laminopathies,
where loss of disease-associated phenotypes can occur with
prolonged culture (Muchir et al., 2004). An additional advantage
of iPSC derivatives is that they contain endogenous levels of
Lamin A/C, unlike traditional systems of ectopic overexpression
of LMNAmutants in myoblasts; or Lmna-mutant mice that often
require homozygous mutations to manifest a phenotype (e.g.,
Arimura et al., 2005), but even then phenotypes in mice can still
be subtle (e.g., Poitelon et al., 2012).
Most studies have focused on iPSCs derived from patients
with HGPS (Lo Cicero and Nissan, 2015), and to a lesser extent
DCM, FPLD, and atypical Werners (Ho et al., 2011; Siu et al.,
2012; Friesen and Cowan, 2017; Lee et al., 2017). Differentiated
FPLD-iPSCs exhibit disease associated defects in differentiation
and lipid metabolism (Friesen and Cowan, 2017). DCM-iPSC
differentiated into fibroblasts (Ho et al., 2011) or cardiomyocytes
(Siu et al., 2012; Lee et al., 2017) show increased nuclear blebbing
or increased rates of apoptosis. While iPSCs from patients with
skeletal muscle laminopathies are available, using them to model
disease pathology has not been reported.
Numerous protocols have been developed to direct
differentiation of iPSCs into myogenic cells (Loperfido et al.,
2015; Kodaka et al., 2017). These approaches can be broadly
categorized into either transgene-based overexpression of
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myogenic regulatory factors such as Pax3, Pax7 or MyoD (e.g.,
Darabi et al., 2012; Tedesco et al., 2012), or transgene-free
systems using growth factors and small molecules to mimic
myogenesis in vitro (reviewed in Chal and Pourquié, 2017;
Kodaka et al., 2017). In this study, we differentiated three iPSC
lines from patients with skeletal muscle laminopathies carrying
Lamin A/C p.K32del, p.L35P, and p.R249W gene mutations into
inducible myogenic cells using our published protocol (Tedesco
et al., 2012; Gerli et al., 2014; Maffioletti et al., 2015). Proliferating
LMNA-mutant inducible myogenic cells cultured as monolayers
had significant abnormalities in nuclear morphology, aggregates
of Lamin A/C and Lamin B1 capping. Terminal myogenic
differentiation and fusion into multinucleated myotubes was
not overtly affected, but mislocalization of Lamin A/C was
only noted in one line, R249W. Although all LMNA-mutant
lines demonstrated some nuclear shape defects in multinucleate
myotubes grown in monolayer culture, these shape defects
became significantly more pronounced when differentiated
in 3D artificial muscle constructs, with an increase in the
proportion of abnormally elongated nuclei.
RESULTS
Differentiation of LMNA-Mutant iPSCs Into
Inducible Myogenic Cells
Three LMNA-mutant iPSC lines derived from patients affected
by skeletal muscle laminopathies were kindly provided by
Cellular Dynamics International Inc. and Cure CMD (Table 1).
Episomal vector-based reprogramming was utilized to generate
iPSC colonies, whose pluripotency was PCR-validated by Cellular
Dynamics International Inc. with a proprietary set of genes using
a Bioanalyzer. Three distinct heterozygous dominant LMNA
mutations were represented by these iPSCs: p.K32del and p.L35P
(both encoded by LMNA exon 1) and p.R249W (encoded by
LMNA exon 4) (Table 1).
LMNA-iPSC were differentiated into inducible myogenic cells
using our protocol that generates an expandable population
of mesodermal cells similar to mesoangioblasts (i.e., HIDEMs:
Human iPSC Derived Mesoangioblast-like cells), which can be
efficiently induced to terminal skeletal myogenic differentiation
by transient expression of the myogenesis regulator MyoD
(Tedesco et al., 2012; Gerli et al., 2014; Maffioletti et al.,
2015). After a 3-week commitment from iPSCs to HIDEMs,
LMNA-mutant cells morphologically resembled control
HIDEMs derived from healthy donors (Maffioletti et al., 2015).
Sequencing confirmed that the lines contained the expected
heterozygous pathogenic LMNA mutations (Figure 1A).
HIDEMs typically exhibit a characteristic profile of cell surface
markers (Tedesco et al., 2012; Maffioletti et al., 2015), and
as expected, the three LMNA-mutant lines expressed CD146,
CD13, CD44, and CD49b at levels similar to previously
generated control cells, and were negative for CD56, CD45 and
CD31 (Supplementary Figure 1A). Immunofluorescence for
the pluripotency-associated markers SOX2 and OCT3/4 was
negative in all three LMNA-mutant lines demonstrating lack
of residual pluripotent cells in the differentiated population
(Supplementary Figure 1B). There was also an absence of
Lamin A/C expression in LMNA-mutant iPSC colonies, with
faint expression only in differentiating cells near the edges of
those colonies (Supplementary Figure 1C). Derivatives of these
three LMNA-mutant iPSC lines have also been recently used
in 3D cultures (Maffioletti et al., 2018) and we provide here
a detailed analysis of their use for modeling skeletal muscle
laminopathies in both conventional cultures and 3D platforms.
LMNA-Mutant Inducible Myogenic Cells
Have Deformed Nuclei
Immunolabeling HIDEMs revealed that the expression of Lamin
A/C and Lamin B1 became detectable as iPSCs differentiated into
inducible myogenic cells. However, amongst the LMNA-mutant
cells with normal circular/oval nuclei shaped were numerous
TABLE 1 | LMNA-mutant iPSC mutations and patient phenotype.
LMNA
exon
cDNA Protein Protein
domain
Cell type Affected
tissue
LMNA-database
mutation reportsb
Cell source
1 c.94_96
delAAG
p.(K32del) Head/
coil 1Aa
iPS cell Skeletal and
heart muscle
5 reports: EDMD (2 cases),
L-CMD (2 cases), asymptomatic
(1 case)
Cure CMD and Cellular
Dynamics International Inc.
1 c.104T>C p.(L35P) Coil 1A iPS cell Skeletal and
heart muscle
(L-CMD)
1 report:
L-CMD (1 case)
Cure CMD and Cellular
Dynamics International Inc.
4 c.745C>T p.(R249W) Coil 2, ERK
1/2 binding
domain
iPS cell Skeletal and
heart muscle
(LGMD1B)
9 reports:
L-CMD (6 cases),
EDMD (2 cases),
Striated muscle laminopathy (1
case)
Cure CMD and Cellular
Dynamics International Inc.
aThe beginning of coil 1A is often stated as amino acid 34 (Capell and Collins, 2006; Captur et al., 2017; UMD-LMNA, 2018), however others report this as position 31 (Scharner et al.,
2010; Tan et al., 2015; Zwerger et al., 2015). Thus, K32del has been reported to be in the head domain (UMD-LMNA, 2018), or in coil 1A (Bank et al., 2011). Since the crystal structure
of the head domain and coil1A has not been solved, the exact domain that this mutation is in remains uncertain.
bLaminopathy disorders reported to be caused by these mutations in the LMNA-Universal mutation database http://www.umd.be/LMNA/.
EDMD, Emery-Dreifuss muscular dystrophy; L-CMD, LMNA-related congenital muscular dystrophy.
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FIGURE 1 | Differentiated LMNA-mutant human iPSCs express Lamin A/C and Lamin B1 and many have an abnormal nuclear shape. (A) Phase contrast images of
the three LMNA mutant inducible myogenic cell lines K32del, R249W and L35P next to their respective electropherograms confirming the expected heterozygous,
dominant, pathogenic LMNA mutations. (B) Representative immunofluorescence panel for Lamin A/C and Lamin B1 proteins showing abnormally-shaped nuclei and
mislocalized Lamin B1 in all LMNA mutant lines (examples highlighted by arrowheads). Nuclei were counterstained with Hoechst. Scale bar: 50µm.
cells with deformed nuclei (non-oval), not observed in control
HIDEMs (Figure 1B). A range of morphological abnormalities
was observed in LMNA-mutant HIDEMs, which we categorized
as deformed (“jellybean” in shape or severely deformed), blebs,
strings, or elongation (defined as >25µm in length) (examples
in Figure 2A). Such deformities in LMNA-mutant cells were
measured using the nuclear contour ratio (Scharner et al., 2011,
2015), which measures how a shape deviates from a circle, with 1
representing a perfect circle and decreasing values representing
an increasing level of deformity. Control cell values typically
ranged from 1 to 0.79; a range describing typical circular to oval-
shaped nuclei within a monolayer culture. By contrast, the mean
nuclear contour ratio of all three LMNA-mutant HIDEM lines
was significantly lower (p.K32del 0.76 ± 0.02 s.d. p = 0.0041
vs. control 1 and p < 0.0001 vs. control 2; R249W 0.75 ±
0.01 s.d. p = 0.0013 vs. control 1 and p < 0.0001 vs. control 2;
L35P 0.79 ± 0.03 s.d. p = 0.0256 vs. control 1 and p = 0.0003
vs. control 2; control 1 mean 0.84 ± 0.03 s.d. and control 2
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FIGURE 2 | LMNA-mutant human iPSC-derived inducible myogenic cells have nuclei with abnormal morphology. (A) Representative examples of immunofluorescence
showing nuclear morphology of LMNA-mutant HIDEMs K32del, R249W, and L35P (high magnification pictures from Figure 1B). Abnormal nuclear morphologies were
classified into five categories: jelly bean, severely deformed, blebs, string or elongated, and examples of each are shown for each cell line, with their corresponding
nuclear contour ratio values. Cells with normally-shaped circular/oval nuclei typically have a nuclear circularity of 1–0.79, whereas nuclear deformity reduces this ratio
(indicated on each panel). Some mislocalization of Lamin A/C is also evident (white arrowheads). Scale bar: 20µm. (B) Nuclear deformity in LMNA-mutant HIDEMs
quantified using the nuclear contour ratio. One-way analysis of co-variance (ANOVA) with Tukey’s post-hoc comparisons performed on the average values of the three
repeats compared to each control line (n = 3, 152–334 nuclei assessed per repeat passage for each cell line); *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001.
Data are box plots generated from all circularity values across three repeats combined (a total of 663–755 nuclei were analyzed per cell line); whiskers: minimum and
maximum values, +: average (specified also at the bottom of each column). (C) Quantification of prevalence of nuclear shape abnormalities, as well as normal shaped
nuclei (circular or oval). Nuclei were considered elongated if they were >25µm along their major axis. When present, nuclei with more than one type of abnormality
were counted twice (e.g., blebs and elongated), so totals can exceed 100%. Number of normal shaped nuclei was compared between LMNA-mutant HIDEMs and
control 1 (ref.1) and control 2 (ref.2). Between 81 and 167 nuclei were analyzed per cell line per repeat, apart from one repeat of control 1 where only 51 nuclei were
assessed (a total of 248–355 nuclei were assessed per cell line). Statistics were performed on the average values of the three repeats (n = 3) compared to each
control line, using one-way analysis of co-variance (ANOVA) with Tukey’s post-hoc comparisons; *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001.
mean 0.91 ± 0.01 s.d.; control 1 vs. control 2 p = 0.0511.
n= 3 one-way ANOVA, Tukey’s multiple post-hoc comparisons)
(Figure 2B).
We then quantified the proportion of each of these types of
abnormality, and found that “deformed” was the most frequent
shape abnormality (jelly bean and severely deformed), followed
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by a much smaller proportion of nuclei showing blebs, strings,
and elongation. There were significantly fewer normal shaped
nuclei in all LMNA-mutant lines compared to both control 1 and
control 2 (p.K32del 55.1± 4.0% s.d. p= 0.0048 vs. control 1 and
p = 0.0057 vs. control 2; R249W 31.0 ± 7.8% s.d. p < 0.0001 vs.
control 1 and p < 0.0001 vs. control 2; L35P 36.0 ± 3.5% s.d.
p = 0.0001 vs. control 1 and p = 0.0001 vs. control 2; control 1
mean 85.6% ± 1.9% s.d. and control 2 mean 85.0 ± 2.0% s.d.;
control 1 vs. control 2 p > 0.9999. n = 3 one-way ANOVA,
Tukey’s multiple post-hoc comparisons; Figure 2C).
In summary, Lamin A/C and B1 are expressed upon
differentiation of LMNA-mutant iPSCs into inducible myogenic
cells, but significantly more deformed nuclei are present in cells
of each of the three pathogenic genotypes analyzed.
Nuclear Envelope Proteins Are
Mislocalized in LMNA-Mutant Inducible
Myogenic Cells
Immunofluorescence analysis indicated that Lamin A/C was
also present in foci and honeycomb patterns; in addition,
there were cells where Lamin B1 was missing from areas
of the nucleus (capping). To better investigate mislocalization
of Lamin A/C and B1, LMNA-mutant lines were imaged by
confocal microscopy. Cells were also immunolabeled for Lamin
A/C, Lamin B1, and Emerin, inner nuclear membrane protein
that associates with the nuclear lamina, whose localization is
dependent on Lamin A (Vaughan et al., 2001). Confocal imaging
showed multiple nuclei with aggregates of Lamin A/C, which
appeared as bright foci or in honeycomb patterns (Figure 3A).
The proportion of Lamin A/C aggregates (honeycomb/foci) was
significantly higher in each of the three differentiated LMNA-
mutant iPSCs compared to each control cell line, with p.K32del
mean 38.4 ± 9.6% s.d. (p = 0.0009 vs. control 1, p = 0.0006
vs. control 2), p.R249W mean 56.8% ± 10.4 s.d. (p<0.0001
vs. control 1, p < 0.0001 vs. control 2), p.L35P mean 41.7 ±
3.0% s.d. (p = 0.0004 vs. control 1, p = 0.0003 vs. control 2),
compared to control 1 mean 4.6% ± 4.0 s.d. and control 2 mean
2.9% ± 2.5 s.d. with no significant difference between control
1 and 2 (p = 0.9977) (one-way ANOVA with Tukey’s multiple
comparison test, n= 3; Figure 3B).
In nuclear regions with Lamin A/C aggregates, there was
typically an absence of Lamin B1 (capping; Figure 3A). The
proportion of cells with nuclear regions lacking Lamin B1 was
significantly higher in LMNA-mutant HIDEMs compared to
both control cell lines (K32del mean 35.8± 7.1% s.d. p= 0.0003
vs. control 1, p= 0.0001 vs. control 2; R249Wmean 55.1± 6.4%
s.d. p < 0.0001 vs. control 1, p < 0.0001 vs. control 2; L35P mean
40.5 ± 5.2% s.d. p < 0.0001 vs. control 1, p < 0.0001 vs. control
2; control 1 mean 6.3 ± 2.4% s.d.; control 2 mean 3.5 ± 3.1%
s.d.; with no significant difference between controls p = 0.9630,
one-way ANOVA with Tukey’s multiple comparison test, n = 3;
Figure 3C).
Occasional foci of Emerin in the LMNA-mutant lines could
be seen; however, even if an increased trend could be observed
in all LMNA-mutant lines compared to control cells, differences
were only statistically significant compared to each control cell
line in R249W. K32del and L35P were significant compared to
control 2 only, but since they were not significant compared
to control 1, Emerin mislocalization was not considered to be
a robust phenotype in these lines (K32del 15.0 ± 1.2% s.d.
p = 0.0553 vs. control 1, p = 0.0335 vs. control 2; R249W 15.4
± 7.1% p = 0.0474 vs. control 1, p = 0.0288 vs. control 2;
L35P 14.1 ± 4.0% s.d. p = 0.0795 vs. control 1, p = 0.0483
vs. control 2; control 1 3.1 ± 1.2% s.d. control 2 1.9 ± 1.9%
s.d., differences between controls n.s. p = 0.9973, one-way
ANOVA with Tukey’s post hoc comparisons, n = 3; Figure 3D).
Thus, LMNA-mutant HIDEMs have significant aggregates (foci,
honeycombing) of Lamin A/C, as well as regions exhibiting loss
(capping) of Lamin B1, typically in regions with Lamin A/C
aggregates. Emerin however, only displays significant aggregates
(foci) in R249W.
Confocal imaging in control 1 HIDEMs also showed a
clear bright rim of peripheral nuclear Lamin A/C as well
as a comparatively weaker signal of nucleoplasmic Lamin
A/C. This effect was seen to a lesser extent in control 2
(Supplementary Figure 2). Distribution of Lamin A/C within
the nucleoplasm was homogenous with a few brighter spots
corresponding to nucleoli. In LMNA-mutant HIDEMs however,
numerous cells lacked this brighter peripheral Lamin A/C rim,
occurring in cells with and without aggregates. Differences in
nucleoplasmic versus peripheral Lamin A/C was quantified using
a ratio of the average fluorescence intensity of the nuclear
periphery divided by the average fluorescence intensity of the
nucleoplasm (Supplementary Figures 2A,B): a ratio above 1
indicates that more Lamin A/C is located at the nuclear periphery
than in the nucleoplasm. Control 1 cells had a significantly
higher Lamin A/C peripheral localization ratio than all LMNA-
mutant lines indicating that Lamin A/C was not correctly
localized to the nuclear lamina (Supplementary Figures 2C,D).
However control 2 cells only had a significantly higher peripheral
localization ratio than L35P. In addition control 1 and control
2 peripheral localization ratios were significantly different
from each other indicating a degree of variability in this
phenotype between healthy cell lines. We therefore considered
the significance of this in vitro phenotype to be unresolved in
HIDEMs.
We also investigated the peripheral localization ratio for
Lamin B1 and Emerin. For Lamin B1, there were no consistent
differences between controls and each patient-derived cell
line (Supplementary Figures 3A–D). For Emerin, Control 1
generally showed significant differences compared to the mutant
times, but control 2 did not (Supplementary Figures 3E–H), so
we again could not resolve the significance of this phenotype in
HIDEMs.
LMNA-Mutant R249W iPSCs Exhibit
Nuclear Abnormalities Upon Terminal
Skeletal Myogenic Differentiation
Skeletal myogenic differentiation of control and LMNA-
mutant HIDEMs was stimulated by tamoxifen-induced
nuclear translocation of a lentivirally-delivered MyoD-
ER transgene (Maffioletti et al., 2015). All LMNA-mutant
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FIGURE 3 | Confocal microscopy analysis in LMNA-mutant human iPSC-derived inducible myogenic cells shows mislocalization of Lamin A/C and Lamin B1. (A)
Immunofluorescence for Lamin A/C, Emerin and Lamin B1 with Hoechst nuclear counterstain, showing aggregates of Lamin A/C protein in K32del, R249W,
(Continued)
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FIGURE 3 | and L35P LMNA-mutant lines using analysis by confocal microscopy. Aggregates were either honeycomb-like in appearance (white closed arrow) or
bright foci (white open arrow). Areas with Lamin A/C honeycombs/foci display a corresponding lack of Lamin B1 (yellow open arrows). Emerin-containing foci were
also detected in some areas containing Lamin A/C foci (yellow closed arrow), however areas with honeycombs of Lamin A/C did not have observable corresponding
honeycombs of Emerin, however Emerin immunolabeling was weak and so may be unable to detect honeycombing. Scale bar represents 10µm. (B) Quantification of
the proportion of LMNA-mutant HIDEMs with mislocalization of Lamin A/C. All LMNA-mutant HIDEMs had significantly more aggregates of Lamin A/C than each
control cell line (ref.1 and 2) (C) LMNA-mutant HIDEMs had a significantly higher proportion of nuclei with Lamin B1 capping (absence at poles of nuclei) compared to
control (ref.1 and 2). (D) Emerin mislocalization was significant for K32del or L35P in comparison to control 2 (ref.2) but not to control 1 (ref.1). In R249W it was
significant compared to both control 1 and 2 (ref.1 and 2). We therefore judged overall this phenotype was only robust in R249W. Lamin A/C, Lamin B1 and Emerin
data were statistically analyzed together using one-way analysis of co-variance (ANOVA), with Tukey’s post-hoc comparisons. This analysis was performed on the
average proportion of mislocalized from three passages per cell line (n = 3, between 82–178 cells analyzed per passage per cell line); *p< 0.05, ***p<0.001, ****p<
0.0001 compared to each control. Data are box plots generated from the proportion of nuclei with mislocalized Lamin A/C per imaging field (24–33 imaging fields per
cell line combined from three repeats, together containing 290–429 nuclei); whiskers: minimum and maximum values, +: average of all imaging fields.
lines and control 2 successfully differentiated with similar
dynamics to form multinucleated myotubes, 4–6 days after
induction. Differentiated cultures were immunolabeled for
Lamin A/C and the sarcomeric protein Myosin Heavy Chain
(MyHC) (Figure 4A). It was apparent that fewer nuclear shape
deformities were present in the differentiated LMNA-mutant
myotubes compared to their undifferentiated counterparts.
Elongated nuclei could be seen in R249W and occasionally
in L35P (Figure 4A). The nuclear contour ratio was used to
quantify nuclear shape deformities in differentiated LMNA-
mutant cultures. A nucleus was considered to be within a
myotube based on three criteria: (1) within a MyHC-positive
structure; (2) if that structure was multinucleated; (3) if there
was nuclear exclusion of MyHC immunosignal.
Quantification demonstrated that only R249W mutant had
myonuclei with a significantly lower contour ratio than control
myonuclei (Figure 4B, red; K32del 0.84 ± 0.03 s.d. p = 0.7704,
R249W 0.69 ± 0.03 s.d. p < 0.0001, L35P 0.81 ± s.d. p = 0.1382,
control 0.87 ± 0.03 s.d, two–way repeat measures ANOVA with
Tukey’s multiple comparisons, n = 3). Comparisons of non-
myonuclei between control and LMNA-HIDEMs showed that
R249W and K32del, but not L35P, had significantly deformed
nuclei compared to control (Figure 4B, blue; K32del 0.81 ±
0.05 s.d. p = 0.0470, R249W 0.80 ± 0.04 s.d. p = 0.0163, L35P
0.84 ± 0.01 s.d. p = 0.2728, control 0.89 ± 0.03 s.d, two–way
repeat measures ANOVA with Tukey’s multiple comparisons,
n = 3). Furthermore, comparisons within each line showed
R249W myotube nuclei were significantly deformed compared
to those outside of the myotube, whereas differences within
K32del, L35P and control were not significant (mean differences:
K32del 0.034 p = 0.0596, R249W −0.1038 p<0.0001, L35P
−0.027 p = 0.1475, control −0.016 p = 0.5461, two–way
repeat measures ANOVA with Sidak’s multiple comparisons,
n= 3).
Analysis of the proportion of normal shaped nuclei in mutant
myotubes and stratification into the type of shape abnormalities
showed that R249W and L35P had significantly fewer normal
shaped myotube nuclei compared to control (K32del 73.3 ±
7.0% s.d. p = 0.4195, R249W 26.1 ± 12.7% s.d. p = 0.0003, L35P
57.1 ± 13.0% s.d. p = 0.0265, control 86.2 ± 0.7% s.d, one–way
repeat measures ANOVA with Tukey’s multiple comparisons,
n = 3; Figure 4C). In R249W this was primarily due to the
presence of abnormally elongated nuclei, in L35P it was mainly
due to deformed, and to a lesser extent elongated, nuclei.
Thus only R249W LMNA-mutant iPSCs produced terminally
differentiated myonuclei with both an abnormal nuclear
contour ratio and increased proportion of shape deformities,
mainly elongation. L35P had a significant proportion of
abnormal shaped nuclei in terminally differentiated myonuclei,
however these shape deformities only produced a subtle
difference in nuclear contour ratios. K32del did not produce
any significant shape defect in terminally differentiated
myonuclei.
LMNA-Mutant R249W iPSC-Derived
Myotubes Have Mislocalized Lamin A/C
We next investigated if the Lamin A/C mislocalization seen
in LMNA-mutant HIDEMs remained in myotubes. Lamin A/C
honeycombing and foci were present in all LMNA-mutant
lines (Figure 5A). However, the proportion of nuclei exhibiting
these mislocalizations were lower than in LMNA-mutant
undifferentiated HIDEMs, and only statistically significant in
R249W compared to control (K32del 12.4± 1.2% s.d. p= 0.3254,
R249W 24.8 ± 14.4% s.d. p = 0.0201, L35P 12.4 ± 1.9% s.d.
p= 0.3123, control 1.3± 0.2% s.d. n= 3, one-way ANOVA with
Tukey’s post-hoc comparisons; Figure 5B).
Lamin A/C can relocate to the nuclear periphery during
myoblast to myotube terminal differentiation, and mutations in
Lamin A/C can lead to a failure of this process (Markiewicz
et al., 2005). We assessed whether the LMNA-mutant lines
were capable of this relocalization. As in LMNA-mutant
HIDEMs differences between LMNA-mutant myonuclei and
control were not significant (Supplementary Figures 2E,F). In
addition, comparisons between HIDEMs and differentiated
myotubes showed that all LMNA-mutant cells had significantly
more Lamin A/C located at the nuclear lamina in myonuclei
compared to HIDEMs (mean difference between myonuclei
minus HIDEMs within each line: K32del 0.18 p = 0.0427,
R249W 0.18 p = 0.0475, L35P 0.3 p = 0.0009, control
0.15 p = 0.1175, n = 3 two-way ANOVA with Sidak’s
post-hoc comparison) (Supplementary Figures 2G,H). Together,
these results demonstrate that during terminal myogenic
differentiation the LMNA-mutant cell lines assessed do not
completely fail to relocate and assemble Lamin A/C into
the nuclear lamina. In addition amongst the genotypes
studied, only R249W had significant Lamin A/C mislocalization
(honeycomb/foci).
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FIGURE 4 | Terminal skeletal myogenic differentiation of LMNA-mutant iPSC-derived myotubes in monolayer culture and analysis of nuclear circularity and shape
abnormalities. (A) Representative immunofluorescence for Lamin A/C and Myosin Heavy Chain (MyHC) on K32del, R249W, and L35P iPSCs HIDEMs induced to
terminal myogenic differentiation by transient expression of a lentivirally-delivered, tamoxifen-inducible MyoD-ER transgene. Elongated nuclei and nuclear blebbing
were visible (arrowheads). Scale bar: 100µm. (B) Quantification of the average nuclear circularity of terminally differentiated LMNA-mutant iPSCs by measuring the
contour ratio of nuclei within myotubes and those outside of myotubes. Refs = control. Data analyzed with two-way repeat measures ANOVA, with Tukey’s post-hoc
test for comparisons to control, and Sidak’s post-hoc comparison for comparisons within each line. n = 3 independent experimental replicates, with 100–270 nuclei
analyzed per cell line per repeat, except for one repeat in K32del where only 57 nuclei were found outside of myotubes. *p < 0.05, ****p < 0.0001. Data are box plots
with the individual circularity values from all three repeats combined (275–715 nuclei per cell line in total). Whiskers: min and max values; +: average of all values. (C)
Quantification of the prevalence of myonuclear shape abnormalities based on criteria established in HIDEMs (Figure 2). When present, nuclei with more than one type
of abnormality were scored twice (e.g., blebs and elongated), so totals exceed 100%. The number of normally shaped nuclei was compared between LMNA-mutant
HIDEMs and control 2 (ref). Between 78 and 348 nuclei were analyzed per cell line per repeat (a total of 260–710 nuclei were assessed per cell line). Statistics were
performed on the average values of the three repeats (n = 3) compared to each control line, using one-way analysis of co-variance (ANOVA) with Tukey’s post-hoc
comparisons; *p < 0.05, ***p < 0.001.
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FIGURE 5 | LMNA-R249W produces Lamin A/C aggregates upon terminal skeletal myogenic differentiation of LMNA-mutant iPSCs in monolayer cultures. (A)
Immunofluorescence for Lamin A/C and MyHC, with a Hoechst nuclear counterstain, showing aggregates of Lamin A/C protein in K32del, R249W, and L35P
LMNA-mutant myotubes upon confocal microscopy analysis. Aggregates were either honeycomb-like in appearance (white open arrow) or bright foci (white closed
arrow). (B) Although aggregates of Lamin A/C were seen in all LMNA-mutant myonuclei, only R249W was significant compared to control (ref.). One-way analysis of
co-variance (ANOVA) with Tukey’s post-hoc comparisons, on the average of three passages (n = 3, between 74 and 156 myonuclei analyzed per passage per cell
line); *p < 0.05 compared to control myotubes. Data are plotted as box plots generated from the proportion of nuclei with mislocalized Lamin A/C per imaging field
(21–56 imaging fields per cell line combined from three repeats, together containing 381 myonuclei); whiskers: minimum and maximum values, +: average of all
imaging fields. Scale bar: 30 µm.
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Three-Dimensional Culture Enhances
in vitro Modeling of Disease-Associated
Nuclear Abnormalities Upon Terminal
Myogenic Differentiation of LMNA-Mutant
iPSCs
Standard skeletal myogenic differentiation in monolayer
of LMNA-mutant iPSCs demonstrates consistent disease-
associated phenotypes in only one of the three pathogenic
genotypes. Therefore, we investigated whether sensitivity
of our platform could be enhanced by altering culture
conditions, such as differentiating cells in three-dimensions
(3D), to produce conditions more closely resembling the in
vivo environment. Our recent work has shown that these
LMNA-mutant iPSCs exhibit nuclear shape abnormalities
when terminally differentiated in 3D artificial muscle
constructs (Maffioletti et al., 2018). However, the precise
resolution of this 3D platform in detecting disease-associated
phenotypes in comparison with monolayers, its mutation-
specific sensitivity and ability to distinguish location of
abnormal nuclei (i.e., myotube from non-myotube nuclei) are
unknown.
All LMNA-mutant lines differentiated in 3D artificial
muscles successfully formedmultinucleatedmyotubes expressing
markers of terminal skeletal myogenic differentiation such as
embryonic MyHC or titin (Supplementary Figure 4). Three-
dimensional computer-generated reconstruction of confocally-
imaged cell monolayers (Figure 6A) or 3D artificial muscle
constructs (Figure 6B) showed numerous elongated myonuclei
within the 3D artificial muscle constructs in all LMNA-mutant
lines (Figure 6 and Supplementary Videos). Quantification of
abnormal shaped nuclei on 3D reconstructed images using
the criteria established with 2D imaging of LMNA-mutant
HIDEMs and monolayer myotubes (Figures 2C, 4C) showed
that both monolayer and 3D artificial muscle had significantly
more abnormal nuclei compared to their respective controls
(monolayer comparisons to control: K32del 30.4 ± 4.5% s.d.
p = 0.0263, R249W 80.5 ± 13.6% s.d. p < 0.0001, L35P
39.2 ±17.7% s.d. p = 0.0028, control 5.0 ± 3.7% s.d.; 3D
artificial muscle comparisons to control: K32del 63.4 ± 10.5%
s.d. p < 0.0001, R249W 73.1 ± 8.9% s.d. p < 0.0001, L35P 78.9
± 5.1% s.d. p < 0.0001, control 8.0 ± 3.4% s.d.; n = 3 two
way ANOVA with Tukey’s post-hoc comparisons; Figure 7A).
However, these differences were more pronounced in the 3D
artificial muscle, with over double the number of abnormal nuclei
detected in K32del and L35P cultures (Figure 7A). Comparisons
within each line between the monolayer and 3D artificial
muscle showed that this difference was statistically significant
in K32del and L35P (Mean difference between monolayer and
3D artificial muscle within each line: K32del 33.0% p = 0.0031,
R249W −7.4% p = 0.8382, L35P 39.7% p = 0.0005, control
3.0% p = 0.9929, n = 3 two-way ANOVA with Sidak’s
post-hoc comparison; Figure 7A). Importantly, these are the
two mutations that did not produce a significant difference
compared to control when assessed for nuclear contour ratio
in monolayer myotubes (Figure 4B). For the R249W mutation
that did produce an abnormal nuclear contour ratio in the
monolayer, there was no increase of abnormal myonuclei in
artificial muscles.
Stratification into types of abnormalities, showed that
elongated nuclei were the most frequent type of shape
abnormality observed (Figures 7B–E). This is consistent with our
previous data in artificial muscles (Maffioletti et al., 2018) and
in contrast to undifferentiated HIDEM cultures, where deformed
(jellybean and severely deformed) were the most frequently
observed morphological defect. Comparisons within each line
showed that 3D cultures produced a significant increase in
elongated myonuclei compared to monolayer culture for K32del
and L35P (Mean difference between monolayer and 3D artificial
muscle within each line: K32del 32.0% p = 0.0092, R249W 0.4%
p > 0.9999, L35P 46.2% p = 0.0003, control 3.0% p = 0.9953,
n = 3 two-way ANOVA with Sidak’s post-hoc comparison)
(Figure 7B). There was no significant increase in the other types
of shape defects between monolayer and 3D artificial muscle
constructs (Figures 7C–E). This demonstrates that culture of
LMNA mutant lines as artificial muscle constructs produces a
higher number of abnormal myonuclei due to an increase in
the number of myonuclei demonstrating an abnormal elongation
(>25µm).
Having identified nuclear elongation as an important
morphological defect, we then compared the mean length of
all myonuclei assayed (Figure 7F). Average nuclear length was
only significantly increased in monolayer cultures for R249W
compared to control (comparisons to control: K32del 22.2 ±
1.1µm s.d. p = 0.2202, R249W 30.0 ± 3.6µm s.d. p < 0.0001,
L35P 21.3 ± 2.4µm s.d. p = 0.4621, control 18.8 ± 0.9µm s.d.;
n = 3 two way ANOVA with Tukey’s post-hoc comparisons)
(Figure 7F). However, in 3D artificial muscle constructs, the
length of myotube nuclei was significantly higher for each of
the LMNA-mutant lines compared to control (comparisons to
control: K32del 25.6 ± 1.9µm s.d. p = 0.0305, R249W 28.9 ±
2.6µm s.d. p = 0.0006, L35P 28.6 ± 1.8µm s.d. p = 0.0009,
control 20.3 ± 0.6µm s.d.; n = 3 two way ANOVA with
Tukey’s post-hoc comparisons) (Figure 7F). This corresponds
to a significant increase in myonuclear length of L35P in
3D artificial muscles compared to monolayer cultures (mean
difference between monolayer and artificial muscle: K32del
3.4µm p = 0.2287, R249W −1.1µm p = 0.9521, L35P 7.3µm
p= 0.0022, control 1.54µm p= 0.8496, n= 3 two-way ANOVA
with Sidak’s post-hoc comparison).
In summary, myogenic differentiation of LMNA-mutant
iPSCs in a 3D microenvironment, coupled with high-resolution
3D nuclear imaging, improves detection of disease-associated
phenotypes in comparison to conventional monolayer cultures
and unravels cellular hallmarks in vitro across multiple
pathogenic genotypes, providing a high-fidelity modeling
platform for skeletal muscle laminopathies.
DISCUSSION
In this study, three LMNA-mutant iPSC lines K32del, R249W,
and L35P from patients affected by skeletal muscle laminopathies
have successfully been differentiated into inducible skeletal
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FIGURE 6 | Abnormally elongated nuclei characterize LMNA-mutant iPSC-derived myotubes differentiated in either monolayer culture or as 3D artificial muscles.
LMNA-mutant HIDEMs K32del, R249W, and L35P were either terminally differentiated into multinucleated myotubes in (A) monolayer cultures or (B) within 3D artificial
muscles. Three dimensional computer-generated reconstructions from confocally-imaged cells immunolabeled for Lamin A/C and the myogenic markers embryonic
myosin (eMyHC) or Titin. Arrows head: abnormally elongated nuclei. Scale bar: 20µM.
myogenic cells and then into terminally differentiated myotubes
in vitro. All three LMNA-mutant iPSC lines showed significant
defects in nuclear morphology when analyzed as proliferating
inducible myogenic cells. Previous studies have shown that
LMNA mutations causing skeletal muscle laminopathies lead to
defects in nuclear shape in primary patient fibroblasts (Favreau
et al., 2003; Muchir et al., 2003, 2004; Tan et al., 2015), murine
C2C12 myoblasts (Favreau et al., 2003; Scharner et al., 2011;
Barateau et al., 2017), as well as primary human myoblasts
(Bertrand et al., 2014).
The R249W mutation is known to cause abnormal nuclear
shape in undifferentiated cells upon transduction into murine
C2C12 and primary human myoblasts in 3D cultures (Scharner
et al., 2011; Bertrand et al., 2014). Primary undifferentiated
human myoblasts in 3D culture with K32del also have an
elongated nuclear shape (Bertrand et al., 2014), but primary
fibroblasts did not have nuclear shape abnormalities (Muchir
et al., 2004). Here, we found that myotube nuclei carrying R249W
had morphological defects in nuclear contour ratio when grown
in monolayer culture, while L35P and K32del did not. However,
all mutations produced a higher proportion of abnormal
myotube nuclei compared to control monolayer cultures
when assessed using three dimensional computer-generated
image reconstruction, with R249W showing the highest. While
abnormal cells were predominantly caused by elongated nuclei in
myotubes, in proliferating inducible myogenic cells, nuclei were
mainly jellybean/severely deformed.
We recently showed nuclear shape defects in K32del, R249W,
and L35Pmyotubes in 3D artificial muscle constructs (Maffioletti
et al., 2018). Here, we extended the analysis and performed
mutation-specific assessment of myonuclear shape and length;
moreover, we directly investigated if 3D artificial muscles provide
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FIGURE 7 | Disease-associated nuclear abnormalities are more prevalent upon terminal myogenic differentiation of LMNA-mutant iPSCs in three-dimensional
cultures. (A) Abnormal K32del, R249W, and L35P myotube nuclei were assessed from the three dimensional computer-generated reconstructions shown in Figure 6,
(Continued)
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FIGURE 7 | based on shape abnormality criteria established in 2D image analysis in LMNA-mutant HIDEMs (Figure 2). Three statistical comparisons of the myonuclei
are shown: LMNA-mutant to control within monolayer culture (ref.1, black), within artificial muscles LMNA-mutant to control (ref.2, green), within each line
comparisons between 2D and 3D artificial muscle (blue). Data analyzed together using two-way ANOVA with Tukey’s post-hoc comparisons for comparisons to
control, and Sidak’s for comparisons within lines on the average of three passages (n = 3, for monolayer cultures 82–154 myonuclei were analyzed per passage per
cell line with a total of 272–410 per cell line, for artificial muscle 37–70 nuclei were analyzed, totaling 124–171 per cell line). Data are shown as box plots of proportion
of abnormal nuclei per imaging field from all three repeats (22–44 total imaging fields per cell line combined from three repeats); whiskers: minimum and maximum
values, +: average of all imaging fields. Values shown on graph: average of three repeats used for statistical analysis. (B–E) Quantification of the different types of
shape abnormality shown in (A), based on criteria established in LMNA-mutant HIDEMs (Figure 2). As in (A), three types of comparisons are shown. Nuclei with more
than one type of shape abnormality (e.g., blebs and elongation) were counted twice, therefore totals can exceed 100%. Data analyzed together using two-way
ANOVA with Tukey’s post-hoc test for comparisons to control, and Sidak’s post-hoc test for comparisons within lines (n = 3). (F) Myonuclear length along the major
nuclear axis. As in (A), three types of comparisons were performed. Data analyzed using two-way ANOVA with Tukey’s post-hoc test for comparisons to control, and
Sidak’s post-hoc test for comparisons within lines (n = 3). Data are shown as a scatter plot comprised of all values from three repeats combined. Bars: mean and
standard deviation. Nuclei were assessed to be part of a myotube based on location within a multinucleated myosin/titin-positives structure, and nuclear exclusion of
myosin/titin. Data for non-myotube nuclei within the culture are not shown. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
better in vitromodeling of nuclear abnormalities than traditional
monolayer cultures in specific LMNA genotypes. Differentiating
HIDEMs in the 3D culture significantly improved modeling
of the nuclear shape defects for K32del and L35P mutations,
with a significant increase in the proportion of abnormally
shaped myotube nuclei in the 3D artificial muscle compared to
monolayer cultures. This was due to an increase in the proportion
of abnormally elongated nuclei, consistent with our previous
report (Maffioletti et al., 2018).
Skeletal muscle biopsies from four patients with
EDMD/LGMD1B revealed that 17% of myonuclei had
an abnormal nuclear shape, although there was no shape
abnormality in satellite cells (Park et al., 2009). In vivo, elongated
cardiomyocyte nuclei have been reported in heart biopsies
of Lmna+/−, Lmna−/− (Nikolova et al., 2004) as well as
LmnaK32del/+ mutant mice (Cattin et al., 2013, 2016). Therefore,
for the types of shape defects observed in patient muscle biopsies
to become more pronounced in skeletal myotubes in vitro, cells
may require some degree of external stress (e.g., mechanical
tension found in a 3D artificial muscle environment) that mimics
in vivo conditions. This mechanical tension could stretch the
nuclei into the elongated shape, with LMNA-mutant nuclei less
able to resist such deformation. In keeping with this notion, an
external stress of electrical stimulation to induce contraction also
produces a phenotype in DCM-iPSC derived cardiomyocytes
which showed no overt shape abnormality at rest (Siu et al., 2012).
Why the skeletal myonuclei require a 3D environment to show
a phenotype, when the proliferative myogenic cells we assessed
did not, is unclear. It could be that skeletal myotubes are more
resistant to deformation and so require more stress to induce
a phenotype. This could potentially be due to differences in
Lamin A/C expression levels or its localization to the periphery.
An alternative, less likely, explanation could be that the most
abnormal cells are lost during prolonged culture or might be
resistant to fusing into myotubes.
K32del, R249W, and L35P mutations also caused significant
honeycomb/foci aggregates of Lamin A/C in proliferating
myogenic cells, consistent with previous reports showing that
R249W causes disorganization of the nuclear lamina lattice
resulting in loss of Lamin A from cell poles (capping) (Scharner
et al., 2011). Primary fibroblasts from patients harboring the
K32del mutation have honeycomb mislocalizations of Lamin
A/C (Muchir et al., 2004), and we also found HIDEMs
with similar mislocalization of Lamin A/C for this mutation.
However, we saw that when terminally differentiated into
skeletal myotubes, only R249W had nuclei with significant
honeycomb/foci of Lamin A/C.
The honeycomb/foci aggregates of Lamin A/C could be
due to a protein assembly defect. In support of this, LMNA
mutations underlying DCM and EDMD cause assembly defects
in vitro (Wiesel et al., 2008; Bank et al., 2012; Bhattacharjee
et al., 2013). Furthermore, when expressed in C. elegans, K46del
(corresponding to K32del in humans) interferes with the lateral
assembly of dimeric head-to-tail polymers into antiparallel
tetrameric filaments, which in vivo result in peripheral nuclear
aggregates in post-larval tissues (Bank et al., 2011).
It is unclear why myonuclei have lower levels of Lamin
A/C mislocalization than proliferative cells. It could be that
nuclei with the most mislocalization are unable to fuse into
myotubes or are progressively lost during culture. Alternatively,
mislocalizations in proliferative nuclei could be easier to resolve
due to differences in Lamin A/C expression level compared to
terminally differentiated myonuclei.
All LMNA-mutant HIDEM lines also had low levels of Lamin
A/C at the nuclear lamina, however we found this phenotype
was inconsistent, as there was significant variability even between
control cell lines. Only L35P consistently showed significantly
less Lamin A/C at the nuclear lamina compared to both control
cell lines. Nonetheless, there was no significant difference in
myonuclear peripheral localization ratio between any LMNA-
mutant line and control cells upon terminal skeletal myogenic
differentiation. Furthermore, we observed relocation of Lamin
A/C to the nuclear periphery in terminally differentiated
skeletal myonuclei at variance with reports showing that skeletal
muscle laminopathy mutations produce a defect in Lamin A/C
relocation to the nuclear periphery during terminal myogenic
differentiation (Markiewicz et al., 2005). Mutations in LMNA
lead to a reduction in the amount of peripheral Lamin A/C in
muscle from Lmnak32del/k32del and LmnaK32del/+ mice (Bertrand
et al., 2012; Pilat et al., 2013) or when overexpressed in murine
C2C12 myoblasts (Ostlund et al., 2001; Markiewicz et al., 2005;
Barateau et al., 2017). Primary humanmyoblasts with K32del and
R249W also have Lamin A/C mislocalized to the nucleoplasm
(Bertrand et al., 2014). From our results it seems that the
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LMNA-mutant lines assessed do not have a complete failure
to relocate and assemble Lamin A/C to the nuclear lamina
during terminal myogenic differentiation. However, the relative
contribution of theWT vs. mutant LMNA allele to this peripheral
Lamin A/C is uncertain and more sensitive quantitative methods
could detect a more subtle difference between patient and control
cells. We believe that due to the variability seen between controls,
modeling this phenotype would benefit from the use of isogenic
controls, for example generated using gene editing technologies.
Within nucleoplasm, Lamin A/C controls Rb
phosphorylation, which is important in regulation of cell
cycle progression and cell cycle exit during terminal myogenic
differentiation. Lamin A/C deficient cells or those harboring
EDMD/L-CMDmutations have defects in muscle differentiation
(Favreau et al., 2004; Markiewicz et al., 2005; Frock et al., 2006;
Gnocchi et al., 2011; Pilat et al., 2013). These differentiation
defects are associated with a lack of proper cell cycle exit and Rb
remaining hyper-phosphorylated (Favreau et al., 2004), as well
as a failure of Lamin A/C to relocate from the nucleoplasm to
the nuclear lamina (Markiewicz et al., 2005). However, we did
not observe overt issues with differentiation into multinucleated
myosin heavy chain positive myotubes. This included K32del,
which causes delayed and insufficient differentiation in mouse,
with a failure to upregulate myosin heavy chain during
LmnaK32del/K32del myoblast differentiation (Pilat et al., 2013).
We used MyoD overexpression to drive differentiation, which
could mask possible defects in the native/spontaneous skeletal
myogenic differentiation programme. Indeed, MyoD can rescue
impaired differentiation seen in mouse Lmna−/− myoblasts
(Frock et al., 2006). Recently, transgene free approaches have
been devised that do not rely on over expression of MyoD
(reviewed in Chal and Pourquié, 2017). Such systems might
be better suited to studying disease-associated alterations in
differentiation potential, and future work in our laboratories will
seek to exploit this methodology.
We also observed loss of Lamin B1 in regions with aggregates
of Lamin A/C, as we previously reported for R249W, which
causes disorganization of the nuclear lamina lattice resulting
in loss of both Lamin A and B1 from cell poles (capping)
when exogenously expressed in murine C2C12 myoblasts
(Scharner et al., 2011). However, we did not see any significant
mislocalization of Lamin B1 from the nuclear periphery when
Lamin A/C was absent, as consistent with previous reports in
LmnaK32del/K32del embryonic muscle sections where Lamin B1
is at the nuclear periphery (Bertrand et al., 2012). Abnormally
shaped nuclei, together with the mislocalization of Lamin B1,
could render the nuclei more susceptible to nuclear rupture.
Areas without Lamin B1 are also often the sites of nuclear
envelope blebbing leading to rupture, which results in loss of
compartmentalization between the nucleus and the cytoplasm
(Lammerding et al., 2004). Indeed, in laminopathy patient
fibroblasts, abnormal shaped nuclei are associated with increased
nuclear rupture (De Vos et al., 2011).
Lamin A/C mutations can cause loss of Emerin at the nuclear
envelope in vitro when overexpressed in C2C12 myoblasts
(Ostlund et al., 2001), and in vivo in C. elegans expressing K46del
(equivalent to human K32del) (Bank et al., 2011). In L35P we
also found significant mislocalization of Emerin from the nuclear
periphery compared to one control only. However, as with Lamin
A/C there was again a significant amount of variability between
control cell lines and so we could not resolve this question.
In conclusion, our work shows that skeletal muscle
laminopathies can be modeled using human iPSCs at different
stages of differentiation. Although nuclear abnormalities could be
observed in proliferating iPSC derivatives, conventional skeletal
myogenic differentiation resulted in less-pronounced disease-
associated phenotypes. Conversely, three dimensional nuclear
analysis of 3D artificial muscles derived from LMNA-mutant
iPSCs resulted in high-fidelity mutation-specific modeling
which was superior to conventional monolayer cultures. Using
LMNA-mutant iPSCs to model muscle laminopathies could
provide the foundations for next-generation therapy screening
platforms to tackle this group of severe and incurable disorders.
MATERIALS AND METHODS
Cell Lines, Culture, and Differentiation
LMNA-mutant human iPSCs were kindly provided by Cellular
Dynamics International Inc. (CDI; https://cellulardynamics.
com) and Cure Congenital Muscular Dystrophy (CureCMD;
https://www.curecmd.org). iPSCs were generated by CDI by
reprogramming samples provided by CureCMD (holder of
clinical information) using episomal vectors. Pluripotency of
iPSC lines was validated by CDI using a proprietary set
of genes using a Bioanalyzer. Culture of LMNA-mutant and
control human iPSCs, their differentiation into inducible
myogenic cells (HIDEMs), and terminal differentiation into
skeletal myotubes was performed as previously described
(Maffioletti et al., 2015). Three-dimensional artificial skeletal
muscles were generated as recently reported (Maffioletti et al.,
2018; Prüller et al., 2018), from HIDEMs differentiated within
hydrogels for 7 days after tamoxifen-induced MyoD nuclear
translocation.
Immunofluorescence Staining and
Microscopy
Cells were washed with PBS, fixed with 4% (w/v)
paraformaldehyde (PFA) for 7min, followed by a further
PBS wash. Fixed cells were permeabilized for 1 h with
permeabilization solution [1% bovine serum albumin (BSA) +
0.2% Triton in PBS]. Cells were then blocked for 30min with
10% donkey or goat serum diluted in permeabilizing solution,
followed by overnight incubation with primary antibodies
diluted in permeabilizing solution. Unbound primary antibody
was removed using three washes of 0.2% Triton in PBS. After
this, cells were incubated for 1 h with secondary antibodies
and Hoechst 33342 diluted in 0.2% Triton in PBS. Unbound
secondary antibody was washed away with two washes of 0.2%
Triton in PBS, followed by one rinse of PBS. Cells were imaged
with an inverted fluorescence microscope. As a control for
non-specific secondary antibody binding, a separate well was
incubated with only secondary antibody.
The following primary antibodies were used: rabbit anti-SOX2
1:100 (Abcam AB97959) mouse anti-OCT3/4 1:100 (Santa Cruz
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sc5279), rabbit anti-NANOG 1:100 (Abcam ab80892), mouse
anti-Lamin A/C 1:250 (Novocastra NCL-LAM-A/C, IgG2b) or
goat anti-Lamin A/C 1:250 (for myogenic differentiation nuclear
contour ratio only, Santa Cruz sc-6215), rabbit anti-Lamin B1
1:2,000 (Abcam ab16048), goat anti-Emerin 1:100 (Santa Cruz
SC8086), mouse anti-myosin heavy chain 1:5 (MF20 clone which
recognizes all myosin heavy chain forms, DSHB hybridoma
bank), mouse anti-embryonic myosin 1:5 (F1.652 DSHB).
Secondary antibodies were all AlexaFluor R© (Life Technologies;
1:500); when mouse anti-Lamin A/C (Novocastra NCL-LAM-
A/C, IgG2b) and mouse anti-embryonic myosin (DSHB F1.652,
IgG1) were used together, IgG-specific AlexaFluor R© secondary
antibodies were also used.
3D hydrogels were immunolabeled as described previously
(Maffioletti et al., 2018). Following fixation with 4% (w/v) PFA
for 3 h at 4◦C and incubation with blocking solution, the primary
antibody mixture consisting of mouse anti-Titin 1:50 (DSHB
9D10, IgM) and mouse anti-Lamin A/C 1:125 (Novocastra NCL-
LAM-A/C, IgG2b) was added. Next day, gels were washed with
TBS six times over the course of a day and incubated with
Hoechst (1:125), goat anti-mouse IgM (488) and goat anti-mouse
IgG2B (546) (1:250). The day after, gels were washed again six
times with TBS, mounted on an indented glass slide (Carl Roth,
H884.1) in Fluoromont G mounting medium (Dako, S3023A)
and imaged using a confocal microscope.
For standard fluorescence microscopy, a Leica DM16000B
inverted microscope with Leica application suite advanced
fluorescence software was used. For confocal fluorescence
microscopy imaging the upright Leica SPE2 was used running
LAS-X software, with a 63X objective and a slice size of 1µm.
Scanning parameters 1,024 × 1,024, speed of 600, zoom factor
1.5 and frame average 3. For confocal imaging, cells were plated
on Labtex II chamber glass slide (Nunc). For confocal analysis
in myotubes, proliferating myogenic cells were differentiated for
4–7 days on Fluodishes (35mm, World Precision Instruments),
coated with matrigel as previously described (Maffioletti et al.,
2015).
Analysis of Nuclear Abnormalities
To perform nuclear contour ratio analysis, abnormalities
in nuclear shape on lamin A/C immunolabelled images
were manually drawn around using the polygon tool
in Fiji imaging software. The area and circumference
measurements were used to quantify the nuclear contour
ratio (4pi area/circumference2) (Goldman et al., 2004). Cells
were imaged using a 32X lens on an inverted microscope for
all nuclear contour ratio quantification. Imaging fields were
randomly selected, and multiple imaging fields were taken
for each repeat (between 3 and 14), with between 150 and
300 cells analyzed. Three repeats of independent cell passages
fixed on different days were analyzed. For each repeat the
nuclear contour ratio was averaged to the number of cells
analyzed.
For shape classification, myonuclei were scored as deformed
(e.g., hook or jelly bean structures), elongated (major axis
>25µm), with blebs (Lamin A/C protrusions), strings
(represented by thin protrusions of Lamin A/C within the
nuclear structure) or normal (circular/oval with no shape
defects) by a blinded researcher. A cut-off of 25µm for abnormal
nuclear elongation was chosen based on a preliminary assessment
of qualitatively elongated nuclei.
For peripheral localization analysis, Lamin A/C, B1 and
Emerin immunolabelled cells were imaged by confocal
microscopy. A 3.5µm stack was taken in the middle of the
nuclei in the Z plane (6 slices of 1µm thickness with a 0.7µm
overlap), and a maximum intensity projection generated. Two
regions were manually drawn around using the polygon tool
in Fiji imaging software: entire nuclei, and the nucleoplasmic
component. Values from these regions were then used to
calculate the peripheral localization ratio (mean average
fluorescence of the nucleoplasm/mean average fluorescence
of the nuclear periphery). Three repeats of independent cell
passages were analyzed. Approximately 16 fields were taken for
each repeat, with 100 cells analyzed for each. For each repeat the
peripheral localization ratio was averaged to the number of cells
analyzed.
Mislocalization analysis of Lamin B1 capping, and aggregates
of Lamin A/C and Emerin was conducted on the same maximum
projections used in the Lamin A/C peripheral localization
analysis. Aggregates of Lamin A/C were scored in two categories:
honeycomb and foci. Honeycomb contained multiple patches
where lamin A/C staining was absent, as opposed to the
usual homogenous staining with a bright peripheral ring and
occasional bright nucleoplasmic nucleoli. Foci were usually
located on the nuclear periphery and were very bright patches
of Lamin A/C staining.
Emerin foci were judged as bright staining patches, as
opposed to the usual evenly distributed peripheral ring.
Emerin immunosignal was too weak to analyse honeycomb
mislocalization reliably. Lamin B1 capping was assessed as nuclei
with regions of absent immunoreactivity, as opposed to its usual
homogenous distribution with a slightly brighter peripheral ring.
For comparisons between 2D monolayer vs. 3D artificial
skeletal muscle, the SPE2 confocal microscope was utilized to
image randomly selected fields with an objective x63, zoom
factor equal to 1.5 and a 0.5µm gap between the slices (2D
monolayer: between 82 and 154 nuclei were analyzed across
10–16 different randomly selected regions per cell line per
repeat; 3D artifical muscle: between 37 and 70 nuclei were
scored across 6–8 different randomly selected fields per cell
line per repeat. Three repeats of independent cell passages
were used). Three-dimensional reconstruction of nuclei was
conducted with Imaris 8.4.1 software (www.bitplane.com). The
3D reconstructions were used for nuclear length measurements
(conducted by measuring the major axis using Imaris 8.4.1
software) and shape classification (conducted as described
above).
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and details of statistical tests are available in the Results section
and in figure legends. Statistical significance was set with a P value
of < 0.05.
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Supplementary Figure 1 | Generation of three LMNA-mutant inducible myogenic
cell lines from laminopathy patient-derived iPSCs. (A) FACS histograms showing
immunophenotype of the K32del, R249W, and L35P LMNA-mutant inducible
myogenic lines is similar to a previously-generated control line (Maffioletti et al.,
2015). (B) Immunofluorescence showing absence of pluripotency-associated
markers SOX2 and OCT3/4 in the differentiated cells (control iPSCs: positive
control). (C) Immunofluorescence panel showing absence of Lamin A/C
expression in a LMNA-mutant iPSC colony, but faint expression in the
differentiating cells delaminating from the same colony. Scale bars: 100µM.
Supplementary Figure 2 | Lamin A/C localization to the nuclear periphery and
nucleoplasm in K32del, R249W, and L35P HIDEMs and myotube nuclei. (A)
Distribution of fluorescence intensity values across the nucleus (dotted line) in
control and LMNA-mutant HIDEMs (K32del shown as a representative example).
(B) Evaluation of peripheral Lamin A/C was calculated by dividing the average
fluorescence intensity of the nuclear periphery (nuclear lamina; b) by the average
fluorescence intensity of the nucleoplasm (a), generating the peripheral localization
ratio. A ratio above 1 denotes more Lamin A/C is located at the nuclear periphery
than the nucleoplasm. (C) Upper bar graph showing Lamin A/C peripheral
localization ratio in LMNA-HIDEMs (only L35P has significantly less peripheral
Lamin A/C in comparison to both controls). (D) Quantification of the proportion of
cells with some degree of peripheral immunolabeling (peripheral/nucleoplasmic
Lamin A/C > 1.05). Only L35P LMNA-mutant HIDEMs had significantly less
peripheral Lamin A/C in comparisons to both control cell lines. (E,F) Analysis
completed as for (C,D) in HIDEMs terminally differentiated into myotubes. Data
show results from myonuclei. (G,H) Direct comparison of values in graphs (C–F)
showing differences between peripheral localization ratios in HIDEMs and
terminally differentiated myonuclei. Nuclear peripheral and nucleoplasmic regions
were manually selected using the polygon tool in Fiji. Three passages were
analyzed per cell line (n = 3), with 61-114 cells analyzed per passage per cell line.
(C,D) One-way ANOVA with Tukey’s post-hoc comparisons to control. (E–H)
Two-way ANOVA with Tukey’s post hoc comparisons to control, and Sidak’s
post-hoc for comparisons between HIDEMs and myonuclei. Data are shown as
box a whiskers plots based on all values from three repeats combined (C and G),
or the proportion of nuclei per imaging field (D and H), whiskers: min and max
values, +: mean of all values plotted, numbers on graph show average of three
repeats. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
Supplementary Figure 3 | Lamin B1 and Emerin localization to the nuclear
periphery and nucleoplasm in K32del, R249W and L35P HIDEMs. (A) Distribution
of Lamin B1 fluorescence intensity values across the nucleus (dotted line) in
control and LMNA-mutant HIDEMs (K32del shown as a representative example).
(B) Evaluation of peripheral Lamin B1 was calculated by dividing the average
fluorescence intensity of the nuclear periphery (nuclear lamina, b) by the average
fluorescence intensity of the nucleoplasm (a), generating the peripheral localization
ratio. A ratio above 1 denotes more Lamin B1 is located at the nuclear periphery
than the nucleoplasm. (C) Upper bar graph showing Lamin B1 peripheral
localization ratio in LMNA-HIDEMs. (D) Quantification of the proportion of cells
with some degree of peripheral labeling (peripheral/nucleoplasmic Lamin B1 >
1.05). No LMNA-mutant HIDEMs had significantly less peripheral Lamin B1 for
both comparisons to control cell lines. (E–H) Data and analyses as in (A–D) for
Emerin. Nuclei peripheral and nucleoplasmic regions were manually selected using
the polygon tool in Fiji. One-way analysis of co-variance (ANOVA), with Tukey’s
post hoc comparisons, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Data are shown as
box a whiskers plots based on all values from three repeats combined (C, E, G),
or the proportion of nuclei per imaging field (D, F, H), whiskers: min and max
values, +: mean of all values plotted, numbers on graph show average of three
repeats.
Supplementary Figure 4 | LMNA-mutant iPSCs myotubes in 3D artificial skeletal
muscle constructs. Representative maximum projections of confocally imaged
human artificial muscle constructs of lines K32del, R249W and L35P
immunolabeled for Lamin A/C and the marker of terminal myogenic differentiation
Titin with all nuclei counterstained with Hoechst. Confocal stacks spanned the
entire z-plane of the gels, each slice was 1µm in thickness with a 0.5µm overlap
with the next slice. Scale bar: 30µm.
Supplementary Video 1 | Three dimensional computer-generated reconstruction
of confocal immunofluorescence showing nuclear morphology (Lamin A/C in red)
and myotubes (eMyHC in green) in a monolayer of healthy donor hiPSC-derived
myotubes.
Supplementary Video 2 | Three dimensional computer-generated reconstruction
of confocal immunofluorescence showing nuclear morphology (Lamin A/C in red)
and myotubes (eMyHC in green) in a monolayer of K32del LMNA-mutant
hiPSC-derived myotubes.
Supplementary Video 3 | Three dimensional computer-generated reconstruction
of confocal immunofluorescence showing nuclear morphology (Lamin A/C in red)
and myotubes (eMyHC in green) in a monolayer of L35P LMNA-mutant
hiPSC-derived myotubes.
Supplementary Video 4 | Three dimensional computer-generated reconstruction
of confocal immunofluorescence showing nuclear morphology (Lamin A/C in red)
and myotubes (eMyHC in green) in a monolayer of R249W LMNA-mutant
hiPSC-derived myotubes.
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Supplementary Video 5 | Three dimensional computer-generated reconstruction
of confocal immunofluorescence showing nuclear morphology (Lamin A/C in red)
and myotubes (eMyHC in green) in a human artificial muscle derived from healthy
donor hiPSCs.
Supplementary Video 6 | Three dimensional computer-generated reconstruction
of confocal immunofluorescence showing nuclear morphology (Lamin A/C in red)
and myotubes (eMyHC in green) in a human 3D artificial muscle derived from
K32del LMNA-mutant iPSCs.
Supplementary Video 7 | Three dimensional computer-generated reconstruction
of confocal immunofluorescence showing nuclear morphology (Lamin A/C in red)
and myotubes (eMyHC in green) in a human 3D artificial muscle derived from
L35P LMNA-mutant iPSCs.
Supplementary Video 8 | Three dimensional computer-generated reconstruction
of confocal immunofluorescence showing nuclear morphology (Lamin A/C in red)
and myotubes (eMyHC in green) in a human 3D artificial muscle derived from
R249W LMNA-mutant iPSCs.
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